核子医学市场规模、份额、成长分析，按诊断剂、治疗剂、应用、最终用户、地区 - 产业预测，2024-2031

2022年全球核医市场规模为91亿美元，从2023年的101.7亿美元成长到2031年的248.3亿美元，预计在预测期（2024-2031）复合年增长率为11.8%。

由于强大的产品平臺和政府支持的旨在提高先进诊断和治疗选择机会的倡议，核医市场正在不断增长。这领域结合了多个领域，利用放射性药物评估器官功能和结构，对于甲状腺癌等疾病的早期发现极为重要。 Betaltin、 Omburtamab和 Ytttrium-90 微球等主要产品目前正处于临床试验阶段。儘管面临新冠肺炎 (COVID-19) 大流行带来的挑战，被列为基本服务的核子反应炉仍在继续运行，提供关键的医疗用品。美国癌症协会强调核医学的紧迫性，前列腺癌的高盛行率和 FDA 最近核准Pluvicto 用于治疗转移病例证明了这一点，并强调了这一医学领域的重要性正在增加。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特分析及影响
  • 竞争公司之间的敌对关係
  • 替代品的威胁
  • 买方议价能力
  • 新进入者的威胁
  • 供应商的议价能力

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 监管环境
• 专利分析
• 案例研究

核子医学市场规模：依诊断分类

• 市场概况
• SPECT（单光子发射电脑断层扫描）
  • Technetium99m
  • 铊201
  • 碘123
  • 其他的
• PET（正子断层扫描）
  • 氟18
  • 铷82
  • 其他的

核子医学市场规模：依治疗方法

• 市场概况
• α发射体
  • 镭223
  • 锕225
• β放射体
  • 碘131
  • 钇90
  • 镏177
• 近距离放射治疗同位素
  • 碘125
  • 钯103
  • 铯131

核子医学市场规模：依应用分类

• 市场概况
• 肿瘤学
  • 甲状腺癌
  • 骨转移
  • 淋巴瘤
• 心臟病学
  • 心肌灌注显像
  • 心室功能影像
• 神经病学
  • 大脑影像
  • 阿兹海默症
• 其他的
  • 胃肠病学
  • 肾臟病学

核子医学市场规模：依最终用户划分

• 市场概况
• 医院
• 诊断中心
• 调查机构

核子医学市场规模：按地区划分

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 西班牙
  • 法国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• GE Healthcare
• Curium Pharma
• Novartis
• Cardinal Health
• Lantheus Medical Imaging
• Bracco Imaging SPA
• Jubilant Life Sciences Ltd
• Nordion（Canada）, Inc.
• Siemens Healthineers
• Bayer AG
• Eckert & Ziegler
• Telix Pharmaceuticals
• NorthStar Medical Radioisotopes, LLC
• Shine Medical Technologies
• Isotopia Molecular Imaging Ltd.
• Institute of Isotopes Co., Ltd.
• Mediso Ltd.
• NTP Radioisotopes SOC Ltd.
• ITM Isotopen Technologien Munchen AG
• Radiopharm Theranostics

结论和建议

Global Nuclear Medicine Market size was valued at USD 9.1 billion in 2022 and is poised to grow from USD 10.17 billion in 2023 to USD 24.83 billion by 2031, growing at a CAGR of 11.8% during the forecast period (2024-2031).

The nuclear medicine market is experiencing growth, driven by a strong product pipeline and supportive government initiatives aimed at enhancing accessibility to advanced diagnostic and therapeutic options. This field combines multiple disciplines, utilizing radiopharmaceuticals to assess organ function and structure, crucial for early disease detection such as thyroid cancer. Key products, including betalutin, omburtamab, and yttrium-90 microspheres, are currently in clinical trials. Despite the challenges posed by the COVID-19 pandemic, nuclear reactors, classified as essential services, continued operations to provide critical medicines. The American Cancer Society highlights the urgency of nuclear medicine, as evidenced by the significant incidence of prostate cancer and the recent FDA approval of Pluvicto for metastatic cases, underscoring the growing importance of this medical specialty.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nuclear Medicine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Nuclear Medicine Market Segmental Analysis

Global Nuclear Medicine Market is segmented by diagnostics, therapeutics, application, end user and region. Based on diagnostics, the market is segmented into SPECT (single photon emission computed tomography) (technetium-99m, thallium-201, iodine-123, others) and PET (positron emission tomography) (fluorine-18, rubidium-82, others). Based on therapeutics, the market is segmented into alpha emitters (radium-223, actinium-225), beta emitters (iodine-131, yttrium-90, lutetium-177) and brachytherapy isotopes (iodine-125, palladium-103, cesium-131). Based on application, the market is segmented into oncology (thyroid cancer, bone metastasis, lymphoma), cardiology (myocardial perfusion imaging, ventricular function imaging), neurology (brain imaging, alzheimer's disease) and others (gastroenterology, nephrology). Based on end user, the market is segmented into hospitals, diagnostic centers and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Nuclear Medicine Market

The Global Nuclear Medicine market is significantly driven by the increasing incidence and prevalence of cancer and cardiovascular disease (CVD). The World Health Organization reported that cancer was the leading cause of death in 2020, resulting in nearly 10 million fatalities, with projections indicating that 19.3 million new cancer cases will be diagnosed annually by 2025. Furthermore, in 2019, CVD was responsible for 17.9 million deaths, making up 32% of global mortality, and this figure is anticipated to climb to 23.3 million by 2030. The critical role of nuclear medicine in early diagnosis and treatment of these diseases is poised to propel market growth as demand for effective medical interventions rises.

Restraints in the Global Nuclear Medicine Market

The global nuclear medicine market faces several constraints, primarily due to the rising adoption of alternative diagnostic methods for various illnesses. While nuclear medicine techniques like PET scans are commonly used for cancer detection and cardiovascular imaging, technologies such as MRI and CT scans are increasingly favored, especially in developing countries. These alternatives are often more cost-effective, leading to greater utilization as they benefit from supportive reimbursement policies. Consequently, the shift towards these imaging modalities is likely to hinder the growth of the nuclear medicine market in the coming years, as healthcare providers opt for these less expensive diagnostic options.

Market Trends of the Global Nuclear Medicine Market

The global nuclear medicine market is witnessing a significant upward trend, driven by ongoing advancements in nuclear medicine therapies. Companies are increasingly focused on developing innovative therapies that showcase superior clinical efficacy compared to traditional treatment options, particularly in oncology and other high-burden diseases. This surge in demand is bolstered by regulatory endorsements, such as the US FDA's approval for Curium's Phase-III trial of lutetium Lu 177 PSMA I&T, a promising radiopharmaceutical targeting prostate cancer. Additionally, the emergence of new therapeutic agents by various market players is further stimulating growth, reflecting a robust pipeline geared toward addressing diverse medical conditions and enhancing patient care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global Nuclear Medicine Market Size by Diagnostics & CAGR (2024-2031)

• Market Overview
• SPECT (Single Photon Emission Computed Tomography)
  • Technetium-99m
  • Thallium-201
  • Iodine-123
  • Others
• PET (Positron Emission Tomography)
  • Fluorine-18
  • Rubidium-82
  • Others

Global Nuclear Medicine Market Size by Therapeutics & CAGR (2024-2031)

• Market Overview
• Alpha Emitters
  • Radium-223
  • Actinium-225
• Beta Emitters
  • Iodine-131
  • Yttrium-90
  • Lutetium-177
• Brachytherapy Isotopes
  • Iodine-125
  • Palladium-103
  • Cesium-131

Global Nuclear Medicine Market Size by Applications & CAGR (2024-2031)

• Market Overview
• Oncology
  • Thyroid Cancer
  • Bone Metastasis
  • Lymphoma
• Cardiology
  • Myocardial Perfusion Imaging
  • Ventricular Function Imaging
• Neurology
  • Brain Imaging
  • Alzheimer's Disease
• Others
  • Gastroenterology
  • Nephrology

Global Nuclear Medicine Market Size by End User & CAGR (2024-2031)

• Market Overview
• Hospitals
• Diagnostic Centers
• Research Institutes

Global Nuclear Medicine Market Size & CAGR (2024-2031)

• North America, (Diagnostics, Therapeutics, Applications, End User)
  • US
  • Canada
• Europe, (Diagnostics, Therapeutics, Applications, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific, (Diagnostics, Therapeutics, Applications, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America, (Diagnostics, Therapeutics, Applications, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa, (Diagnostics, Therapeutics, Applications, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• GE Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curium Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus Medical Imaging
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bracco Imaging S.P.A
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Life Sciences Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nordion (Canada), Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eckert & Ziegler
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Telix Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NorthStar Medical Radioisotopes, LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shine Medical Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Isotopia Molecular Imaging Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Institute of Isotopes Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mediso Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NTP Radioisotopes SOC Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ITM Isotopen Technologien Munchen AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Radiopharm Theranostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation